These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 19217510)
1. Advanced lipoprotein testing: recommendations based on current evidence. Lau JF; Smith DA Endocrinol Metab Clin North Am; 2009 Mar; 38(1):1-31. PubMed ID: 19217510 [TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036 [TBL] [Abstract][Full Text] [Related]
3. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Miller M; Ginsberg HN; Schaefer EJ Am J Cardiol; 2008 Apr; 101(7):1003-8. PubMed ID: 18359322 [TBL] [Abstract][Full Text] [Related]
4. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Stein EA; Sniderman A; Laskarzewski P Am J Cardiol; 2005 Nov; 96(9A):36K-43K; discussion 34K-35K. PubMed ID: 16291013 [TBL] [Abstract][Full Text] [Related]
6. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Denke MA Circulation; 2005 Nov; 112(22):3368-70. PubMed ID: 16316961 [No Abstract] [Full Text] [Related]
7. [Small dense LDL concentration is closely associated with serum apolipoprotein B, comparisons of non-LDL cholesterol or LDL cholesterol]. Hayashi T; Hirano T; Shiobara T; Suguro T; Adachi M Rinsho Byori; 2006 Jun; 54(6):569-75. PubMed ID: 16872005 [TBL] [Abstract][Full Text] [Related]
9. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Andrikoula M; McDowell IF Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887 [TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is.. Sniderman AD Circulation; 2005 Nov; 112(22):3366-7. PubMed ID: 16316960 [No Abstract] [Full Text] [Related]
11. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Grundy SM; Vega GL; Tomassini JE; Tershakovec AM Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610 [TBL] [Abstract][Full Text] [Related]
12. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy. Walldius G; Jungner I Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989 [TBL] [Abstract][Full Text] [Related]
13. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW; Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709 [TBL] [Abstract][Full Text] [Related]
14. [The use of apolipoprotein B in clinical practice to determine the risk for atherosclerosis]. Cabezas Castro M; Liem A Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1445-8. PubMed ID: 12908345 [TBL] [Abstract][Full Text] [Related]
15. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224 [TBL] [Abstract][Full Text] [Related]
16. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study. Magnussen CG; Raitakari OT; Thomson R; Juonala M; Patel DA; Viikari JS; Marniemi J; Srinivasan SR; Berenson GS; Dwyer T; Venn A Circulation; 2008 Jan; 117(1):32-42. PubMed ID: 18071074 [TBL] [Abstract][Full Text] [Related]
17. [Apolipoprotein B and LDL cholesterol: which parameter(s) should be included in the assessment of cardiovascular risk?]. Bloch S; Couderc R Ann Biol Clin (Paris); 1998; 56(5):539-44. PubMed ID: 9769484 [TBL] [Abstract][Full Text] [Related]
18. Changes in lipid metabolism in postmenopausal Japanese women using hormone therapy evaluated by capillary isotachophoresis: a pilot study. Inoue Y; Zhang B; Sadamori R; Shirota K; Saku K; Kawarabayashi T Menopause; 2008; 15(1):157-63. PubMed ID: 17603392 [TBL] [Abstract][Full Text] [Related]
20. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Grover SA; Kaouache M; Joseph L; Barter P; Davignon J Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]